Skip to main content
Download PDF

Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study

BMC Endocrine Disorders volume 23, Article number: 268 (2023) Cite this article

Abstract

Background

Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country.

Methods

This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at < 200 mg/dL for total cholesterol (TC), < 150 mg/dL for triglyceride (TG), < 100 mg/dL for low-density lipoprotein cholesterol (LDL-C), > 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and < 160 mg/dL for non-HDL cholesterol (non-HDL-C).

Result

Three thousand sixty patients (age 44.7 ± 13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels < 70 mg/dL. Only 10.03% achieved the HbA1c target of < 7%. 7.4% of patients achieved both HbA1c < 7% and LDL < 100 mg/dL and 5% achieved both HbA1c < 7% and LDL < 70 mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL < 100 mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control.

Conclusion

Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.

Peer Review reports

Introduction

Type 2 diabetes mellitus (T2DM) has recently become a major global health concern, especially in lower and middle-income countries. Globally, more than 537 million people are affected by T2DM, contributing to almost 11% of deaths annually [1, 2]. Cardiovascular diseases (CVD) dominate the causes of mortality in these patients, which is attributable to approximately two third of the total deaths of these patients [3, 4].

The typical pattern of dyslipidemia, often called ‘diabetic dyslipidemia,’ is characterized by elevated levels of triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and normal to mildly elevated low-density lipoprotein cholesterol (LDL-C) [5, 6]. This pattern of lipid abnormality results from hepatic overproduction of TG-rich very-low-density lipoprotein (VLDL) particles and accelerated exchange of TG in VLDL for cholesteryl esters in HDL-C and LDL-C [7]. Dyslipidemia is common in patients with T2DM. Different reports suggest that more than two-thirds of the patients with T2DM have dyslipidemia [8,9,10,11,12,13]. Diabetic dyslipidemia is particularly prevalent in developing countries due to inadequate diagnosis and proper management [14]. Bangladesh is a lower-middle-income country in the Southeast Asian region. More than 13 million people in this country are affected by T2DM [15, 16]. A recent report suggests that more than 71% of males and 73% of females with T2DM in the country have dyslipidemia [17].

A body of evidence demonstrates that lipid-lowering therapy has a cardioprotective role in patients with T2DM. It is evidenced that intensive statin regimes reduce the risk of major vascular events such as myocardial infarction and stroke by 15%, without significant side effects. Moreover, LDL-C reduction of 1 mmol/L (38.67 mg/dL) results in approximately 23% reduction in CVD events. For these reasons, statins are considered first-line treatments for lipid control in many patients with T2DM, even at diagnosis. In those patients with multiple risk factors for CVD, high-dose statin is recommended [18].

However, despite using statins, achieving optimum lipid control among patients with T2DM is challenging. For example, a study conducted in China indicated that only half of the patients achieved LDL-C control with their lipid-lowering agent [8]. Similar findings were also reported from South Africa [12]. An analysis in Europe and Canada showed that the total cholesterol (TC) and LDL-C control rates were 48% and 55% in statin-using T2DM patients [19]. In this context, evaluating lipid control status among patients with T2DM who are on lipid-lowering drugs is necessary for optimal therapeutic outcomes. Hence, the present study aimed to evaluate the proportion of patients with lipid control and identify associated factors among individuals living with diabetes receiving outpatient care in Bangladesh from January 2022 to December 2022.

Methods

Study design and setting

The present cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. The hospitals are located in divisional and district-level cities and cover all eight administrative divisions of the country. All clinics provide specialist and referral services to patients from the relevant catch-up areas by specialist endocrinologists.

All the patients who visited the diabetes outpatient departments of the hospitals within the study period were considered the study population. The sample size for the present study had been calculated from the following formula: n = z2p(1-p)/d2, where p = estimated prevalence and d = precision of error. Based on previous evidence of the prevalence of lipid control among patients with T2DM as 50% [19], we calculated the sample size as 384. However, we included a total sample of 3060 patients with T2DM for better statistical inference. Inclusion criteria for the present study were male and female patients aged ≥ 18 years, diagnosed with T2DM for at least one year, and were on a minimum of 3 months of lipid-lowering therapy. Pregnant and lactating women, patients with other types of DM, and those with familial dyslipidemias and uncorrected secondary causes of dyslipidemia were excluded. Patients with incomplete information were also excluded. The study included all the patients meeting the inclusion criteria; consecutive sampling was used.

Data collection

Data was collected through face-to-face interviews, review of medical records, and clinical examinations. The interviews were carried out by attending physicians using a semi-structured questionnaire that included socio-demographic information, diabetes-related information, presence or absence of comorbidities and complications of diabetes, including ischemic heart disease (IHD), peripheral vascular disease (PVD), stroke, chronic kidney disease (CKD), diabetic neuropathy, and diabetic retinopathy. Information about comorbidities was retrieved from the medical records of the patients. Hypertension (HTN) was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or currently taking antihypertensive drugs and/or self-reported history of hypertension and antihypertensive drugs. Body mass index (BMI) was calculated by height and weight and categorized as underweight (< 18.5 kg/m2), normal (18.5–22.9 kg/m2), overweight (23–24.9 kg/m2), and obese (≥ 25 kg/m2) according to the World Health Organization cutoff values for the Asian population [17]. Types of glucose-lowering drugs (oral, insulin, or combination therapy) were also recorded. Details of lipid-lowering medications, including generic name, class, and dosage, were recorded.

The laboratory data included the fasting lipid profile, including total TC, TG, HDL-C, and LDL-C. Fasting blood samples were collected following an overnight (8 to 12 h) fasting, and lipids were measured, including direct measurement of LDL-C, using an automatic analyzer in the laboratory of the corresponding center. Hemoglobin A1c (HbA1c) was also measured in the laboratories using the methods certified by the National Glycohemoglobin Standardization Program.

Outcome measures

The lipid control status of the patients with T2DM who were receiving lipid-lowering agents was the outcome measure of the present study. The primary outcome was to determine the proportion of patients with T2DM who achieved LDL-C levels < 100 mg/dL [18] The secondary outcomes of the study were to determine the proportion of patients with T2DM who achieved total cholesterol of less than 200 mg/dL, triglycerides of less than 150 mg/dL, LDL-C of less than 100 mg/dL, and non-HDL-C of less than 160 mg/dL [18]. The secondary outcomes also included the proportion of patients with atherosclerotic cardiovascular diseases (ASCVD that includes IHD, stroke, and PVD) and/or CKD who achieved LDL-C < 70 mg/dL, as well as determining the proportion of patients who achieved both HbA1c < 7% and LDL-C < 100 mg/dL and HbA1c < 7% and LDL-C < 70 mg/dL [18].

Statistical analysis

All the statistical analyses were done using STATA version 17.0 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC). Descriptive statistics like frequencies and percentages for categorical variables and means with standard deviations (SD) or medians with interquartile ranges (IQR) and percentiles for numerical variables were calculated. Finally, a multiple logistic regression model was constructed including all the potential covariates determined from review of existing literature to determine the factors associated with lipid control among the study subjects. A two-sided p-value of < 0.05 was considered to be statistically significant.

Ethical considerations

The study received ethical permission from the institutional review board of Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh (Ref. no.: BSMMU/2021/4786–211; Date: 20 November 2021). Informed written consent was taken from the study subjects. The researcher ensured confidentiality by assigning a study number to each file to record clinical data on the datasheet without recording personal information. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki.

Result

Sociodemographic characteristics

A total of 3060 patients with T2DM were included in the present study, with a mean age of 44.7 (SD 13.3) years. Almost one-third of these patients are aged between 41 to 50 years. Nearly 57% of the participants were female and hailed from urban areas (Table 1).

Table 1 Sociodemographic characteristics of the participants (N = 3,060)
Full size table

Most participants were overweight/obese (93.5%), with a mean BMI of 27.2 (SD 4.3); almost 89% had abdominal obesity. Almost 63.8% of the participants were suffering from T2DM for less than five years while almost 21.7% were suffering from 21.7%. Nearly half of the patients were on oral glucose-lowering drugs, 10% were on insulin, and 40% were on combined therapy of oral agents and insulin. 72.3% of them had comorbid diseases; HTN was the most common comorbidity, with a prevalence of 68.2% (Table 1).

Most (84.7%) patients had diabetic complications; IHD was present in 71.2%, diabetic neuropathy in 62.7%, PVD in 40.9%, and diabetic nephropathy in 39.3% of the participants. Most (90%) patients had poor glycemic control with a mean HbA1c level of 9.5% (SD 2.3). The majority (95.4%) of the patients were on moderate-intensity statin therapy (Atorvastatin 10–20 mg or Rosuvastatin 5–10 mg), only 0.75% were on high-intensity statin therapy (Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg) while 3.9% were on non-statin therapy (Fenofibrate) (Table 1).

Lipid control status

Almost 81% of patients with T2DM achieved the LDL-C target of < 100 mg/dL. Besides, targets of TC < 200 mg/dL, TG < 150 mg/dL, HDL-C > 40 mg/dL, and non-HDL-C < 160 mg/dL were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in almost 8.8% of patients (Fig. 1). Almost 77.6% of patients with IHD, 81.5% with stroke, 81.5% with PVD, and 65% with CKD had LDL-C levels < 70 mg/dL. Moreover, almost 66.7% of the patients from high-risk group (either having cardiovascular disease and/or chronic kidney disease) achieved the target of LDL-C levels < 70 mg/dL. Almost 7.4% of study subjects achieved both of the HbA1c target of < 7% as well as LDL-C target of < 100 mg/dL; 5% achieved HbA1c < 7% and LDL-C < 70 mg/dL.

Fig. 1
figure 1

Lipid control status among patients with T2DM (a overall, b according to gender, c according to BMI, d according to hypoglycemic drugs)

Full size image

Factors associated with lipid control

In the logistic regression model, it was found that older age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001) and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL-C < 100 mg/dL). On the other hand, using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control (LDL-C < 100 mg/dL) (Table 2).

Table 2 Factors associated with lipid control among patients with T2DM (Multiple logistic regression model)
Full size table

Discussion

Attaining lipid targets is crucial in diabetes management, as dyslipidemia increases the risk of cardiovascular morbidity and mortality in these patients. Hence, lipid-lowering therapy is recommended as a preventive measure for patients with T2DM. Despite lipid-lowering therapy, achievement of lipid targets is a hefty task. The present study was conducted to determine lipid control among patients with T2DM in Bangladesh who were receiving lipid-lowering drugs.

In the present study, almost 81% of patients with T2DM who were receiving lipid-lowering drugs achieved their LDL-C target of < 100 mg/dL. Though achievement of the target for individual lipid components was comparatively high in this study, overall lipid control was observed in only 8.8% of the patients. Moreover, only 7.4% of the patients achieved the HbA1c target < 7% and LDL-C target < 100 mg/dL, and 5% achieved HbA1c level < 7% and LDL-C level < 70 mg/dL.

All the patients in our study were on lipid-lowering drugs, mostly statins, such as different doses of rosuvastatin and atorvastatin. Despite lipid-lowering therapy, most patients did not achieve optimum lipid control. This phenomenon among patients with T2DM is not unique to Bangladesh and has been observed in different studies with varying prevalence. A recent meta-analysis including 24 studies from 20 countries reported that almost 49% of patients with T2DM achieved the target for LDL-C, 58% for HDL-C, and 62% for TG control [17]. A study from India, the neighboring country of Bangladesh, reported that almost 41.5% of the patients with T2DM on lipid-lowering therapy achieved the target level of LDL-C [19]. A study from South Africa observed a similar phenomenon where almost 87% of the patients with T2DM who were on lipid-lowering agents did not achieve lipid control [20]. The primary goal of statin therapy for lipid management is to lower LDL-C levels as it significantly reduces the risk of CVD and mortality in patients with T2DM [21].

In our study, a good number of patients achieved LDL-C control. However, almost 19% of the patients had LDL-C above target and remained at risk of major CVD events despite statin therapy. A study conducted in China indicated that almost half of the patients achieved LDL-C control with their lipid-lowering agents [8]. Similar findings were also reported from South Africa [20]. An analysis in Europe and Canada showed that the TC and LDL-C control rates were 48% and 55% in T2DM patients using statins [22]. High TG and low HDL levels contributed to the predominant uncontrolled lipid profile in the present study. Isolated hypertriglyceridemia was attributable to almost 44% of the overall uncontrolled lipid profile. A similar pattern of lipid control was also observed in previous studies from different countries [8,9,10, 12, 20]. In patients with T2DM, insulin resistance and hyperglycemia lead to elevated levels of triglycerides, which culminates in the overproduction of glycerol-rich lipoproteins by the liver. Increasing TG-rich lipoproteins reduce HDL-C production and additional LDL-C production [23, 24]. On the other hand, high TG and low HDL-C can lead to insulin resistance, resulting in poor glycemic control, creating a vicious cycle.

The failure to achieve optimum lipid control despite lipid-lowering intervention might be associated with various factors.

In the present analysis, we found that advanced age, long-standing diabetes, and non-statin lipid-lowering therapy increased the risk of uncontrolled lipid status in patients with T2DM. Though we observed a comparatively lower prevalence of lipid control among male patients, it was not statistically significant. Most of the patients included in our study were overweight or obese, which might hinder lipid control, though it was not found significant in the present study [25]. Though in our study, the duration of T2DM had a positive association with uncontrolled lipid profile, the association of glycemic status was insignificant. However, in recent studies, HbA1c has been suggested to have a linear relationship with uncontrolled lipid profiles, and HbA1c could reflect cholesterol and LDL-C levels among patients with T2DM. A marked increase in total cholesterol and triglyceride levels and a decrease in HDL levels were observed in patients with poor glycemic control compared to patients with good glycemic control [26, 27].

The present study is one of the largest and most recent pieces of evidence to depict the characteristics of the lipid control status among patients with T2DM in Bangladesh. The findings might have significant public health implication. It might be hypothesized that, patients who were on lipid lowering agents in our study, were not conscious about their medication and lifestyle which in turn would increase the disease burden of CVD in near future. Adequate public health awareness programs should be designed to increase medication efficacy in these patients. However, our study had several limitations that would be worth mentioning. All the patients included in our study were on lipid-lowering agents. Hence, our findings might not represent the actual scenario of dyslipidemia among the overall patient population of T2DM. First, our analyses were confined to patients attending different tertiary health facilities. Second, we did not evaluate patients' adherence and duration of lipid-lowering therapy. Moreover, recall and social desirability bias are inherent limitations in such a context. Fourth, our defined target of LDL as < 100 mg/dL might be higher than some guidelines, suggesting a lower target of < 70 mg/dL. Fifth, uncontrolled lipid profile due to secondary drug causes, such as thiazide diuretics and beta-blockers, was not quantified and could not completely be ruled out as a confounding factor. Moreover, being a tertiary care facility-based study including subjects, most of whom had diabetic complications, it might represent a particular patient population at the highest CVD risk and with difficult-to-control lipid profiles, which limits the generalizability of the findings. Finally, because we used cross-sectional surveys, the changes observed reflect only the risk profiles of the diabetes population at the time of the individual surveys [28, 29].

Conclusion

Our study evidenced that few patients with T2DM who were on lipid-lowering therapy achieved the ultimate target for both glycemic and lipid status. However, the majority of the patients achieved their target for LDL control. Uncontrolled lipid profile is mostly attributable to high TG and low HDL-C levels among patients with T2DM in Bangladesh despite having lipid-lowering therapy. Advanced age, duration of diabetes, and non-statin therapy were found to increase the risk of uncontrolled lipid profile among these patients. Our findings draw the attention of policymakers to increase accessibility to potent lipid-lowering agents as well as clinicians for adequate management of hyperlipidemia in patients living with diabetes.

Availability of data and materials

Patient-level data will be available on request from the corresponding author.

Abbreviations

BMI:

Body Mass Index

CKD:

Chronic Kidney Disease

CVD:

Cardiovascular Diseases

HDL-C:

High-Density Lipoprotein Cholesterol

IQR:

Interquartile Ranges

LDL-C:

Low-Density Lipoprotein Cholesterol

T2DM:

Type 2 Diabetes Mellitus

TC:

Total Cholesterol

TG:

Triglyceride

VLDL:

Very-Low-Density Lipoprotein

References

  1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

    Article  PubMed  Google Scholar 

  2. Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108086.

    Article  PubMed  Google Scholar 

  3. Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:1–7.

    Article  Google Scholar 

  4. Jagannathan R, Patel SA, Ali MK, Narayan KV. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr DiabRep. 2019;19:1–12.

    Google Scholar 

  5. Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study. J Am Heart Assoc. 2021;10:e016947.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63:1469–79.

    Article  CAS  PubMed  Google Scholar 

  7. Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in china. JAMA Netw Open. 2021;4:e2127573–e2127573.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in thailand. Lipids Health Dis. 2019;18:1–8.

    Article  Google Scholar 

  10. Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr. 2019;13:2387–92.

    Article  PubMed  Google Scholar 

  11. Li J, Nie Z, Ge Z, Shi L, Gao B, Yang Y. Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in northwest china: a cross-sectional study. Lipids Health Dis. 2022;21:1–9.

    Article  CAS  Google Scholar 

  12. Pitso L, Mofokeng TRP, Nel R. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central south africa. BMC Endocr Disord. 2021;21:1–10.

    Article  Google Scholar 

  13. Jameson K, Amber V, D’oca K, Mills D, Giles A, Ambegaonkar B. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care–a retrospective database study. Int J Clin Pract. 2013;67:1228–37.

    Article  CAS  PubMed  Google Scholar 

  14. Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones. 2018;17:61–7.

    Article  PubMed  Google Scholar 

  15. Akhtar S, Nasir JA, Sarwar A, Nasr N, Javed A, Majeed R, et al. Prevalence of diabetes and pre-diabetes in Bangladesh: a systematic review and meta-analysis. BMJ Open. 2020;10:e036086.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hossain MB, Khan MN, Oldroyd JC, Rana J, Magliago DJ, Chowdhury EK, et al. Prevalence of, and risk factors for, diabetes and prediabetes in Bangladesh: evidence from the national survey using a multilevel poisson regression model with a robust variance. PLOS Global Public Health. 2022;2:e0000461.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Das H, Banik S. Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: a cross-sectional study. Diabetes Metab Syndr. 2019;13:252–7.

    Article  PubMed  Google Scholar 

  18. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes care. 2023;46(Suppl 1):S158–90. https://doi.org/10.2337/dc23-S010.

    Article  CAS  PubMed  Google Scholar 

  19. Sillars A, Sattar N. Management of lipid abnormalities in patients living with diabetes. Curr Cardiol Rep. 2019;21:1–8.

    Article  Google Scholar 

  20. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221–30.

    Article  PubMed  Google Scholar 

  21. World Health Organization, International Association of Study of Obesity, International Obesity Task Force. The Asia-Pacific Perspective. Redefining obesity and its treatment. 2000.  http://www.wpro.who.int/nutrition/documents/Redefining_obesity/en/. Accessed 10 June 2023.

  22. Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137–48.

    Article  PubMed  Google Scholar 

  23. Anjana RM, Unnikrishnan R, Deepa M, Venkatesan U, Pradeepa R, Joshi S, et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in india (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022;10:430–41.

    Article  CAS  PubMed  Google Scholar 

  24. Mirbolouk M, Blaha MJ. ACC/AHA lipid guidelines: personalized care to prevent cardiovascular disease. Cleve Clin J Med. 2020;87:231.

    Article  PubMed  Google Scholar 

  25. Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. Curr Vasc Pharmacol. 2017;15:566–75.

    Article  CAS  PubMed  Google Scholar 

  26. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin. 2006;35:491–510.

    Article  CAS  Google Scholar 

  27. Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B. Interaction between adipocytes and high-density lipoprotein: new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis. Lipids Health Dis. 2019;18:1–11.

    Article  Google Scholar 

  28. Jang J, Kim Y, Shin J, Lee SA, Choi Y, Park E-C. Association between thyroid hormones and the components of metabolic syndrome. BMC Endocr Disord. 2018;18:1–9.

    Article  Google Scholar 

  29. Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Ther Adv Endocrinol Metab. 2017;8:51–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to express their sincere gratitude to Pi Research Development Center, Dhaka, Bangladesh (www.pirdc.org), for their help in manuscript revision and editing.

Funding

The authors have no support or funding to report.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh

    Shahjada Selim & Marufa Mustari

  2. Department of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh

    Muhammad Shah Alam

  3. Department of Endocrinology, Rangpur Medical College, Rangpur, Bangladesh

    Samir Kumar Talukder & Md Lutful Kabir

  4. Department of Pathology, Naogaon Medical College, Naogaon, Bangladesh

    Abu Jar Gaffar

  5. Department of Endocrinology, TMSS Medical College, Bogura, Bangladesh

    Md Ahamedul Kabir

  6. Department of Endocrinology, Bangladesh Institute of Health Sciences, Dhaka, Bangladesh

    Nusrat Zarin

  7. Department of Endocrinology, BIRDEM General Hospital, Dhaka, Bangladesh

    Shahin Ibn Rahman

  8. Department of Endocrinology, Rajshahi Medical College, Rajshahi, Bangladesh

    Md Masud Un Nabi

  9. Department of Endocrinology, Mugda Medical College, Dhaka, Bangladesh

    Md Firoj Hossain

  10. Department of Orthopedic Surgery, Mugda Medical College & Hospital, Dhaka, Bangladesh

    Ahmed Ifrad Bin Raunak

  11. Department of Endocrinology, Sher-E-Bangla Medical College, Barishal, Bangladesh

    Md Azizul Hoque

  12. Department of Neurology, BIRDEM General Hospital, Dhaka, Bangladesh

    Md Rashedul Islam

  13. Department of Endocrinology, Chittagong Medical College, Chittagong, Bangladesh

    Farhana Akter

  14. Department of Endocrinology, North East Medical College, Sylhet, Bangladesh

    Mohammad Abdul Hannan

  15. Department of Endocrinology, Dhaka Medical College, Dhaka, Bangladesh

    Mohammad Saifuddin

  16. Department of Endocrinology, Shaheed Sheikh Abu Naser Specialized Hospital, Khulna, Bangladesh

    Md Asaduzzaman

  17. Department of Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh

    Mohammad Motiur Rahman

  18. Department of Endocrinology, National Institute of Traumatology and Orthopaedic Rehabilitation (NITOR), Sher-E- Bangla Nagar, Dhaka, Bangladesh

    Afsar Ahammed

  19. Pi Research Development Center, Dhaka, Bangladesh

    Md Abdur Rafi

  20. Tropical Disease and Health Research Center, Dhaka, 1100, Bangladesh

    Mohammad Jahid Hasan

  21. Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh

    A. B. M. Kamrul-Hasan

Authors
  1. Shahjada Selim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Shah Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samir Kumar Talukder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Md Lutful Kabir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abu Jar Gaffar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Md Ahamedul Kabir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nusrat Zarin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shahin Ibn Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Md Masud Un Nabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marufa Mustari
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Md Firoj Hossain
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ahmed Ifrad Bin Raunak
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Md Azizul Hoque
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Md Rashedul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Farhana Akter
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Mohammad Abdul Hannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Mohammad Saifuddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Md Asaduzzaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Mohammad Motiur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Afsar Ahammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Md Abdur Rafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mohammad Jahid Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. A. B. M. Kamrul-Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, S.S., M.S.A., M.J.H., and A.B.M.K.H.; formal analysis, M.A.R., M.J.H., A.B.M.K.H and S.S.; investigation, M.L.K., A.J.G., M.A.K., N.Z., S.I.R., M.M.U.N., M.M., M.F.H., A.I.B.R., M.A.H., and M.R.I.; methodology, M.R.I., F.A., A.A., M.AH., M.S., M.A., M.M.R., and S.K.T.; resources, M.S.A., S.K.T., M.L.K., A.J.G., M.A.K., N.Z., S.I.R., M.M.U.N., M.M., M.F.H., A.I.B.R., A.A., M.A.H., M.R.I., F.A., M.AH., M.S., M.A., and M.M.R.; supervision, S.S., and A.B.M.K.H.; writing – original draft, S.S., M.S.A., S.K.T., M.L.K., A.J.G., M.A.K., N.Z., S.I.R., M.M.U.N., M.M., M.F.H., A.I.B.R., M.A.H., M.R.I., A.A., F.A., M.AH., M.S., M.A., M.M.R., M.A.R., M.J.H., and A.B.M.K.H.; writing – review & editing, M.A.R., M.J.H., S.S., and A.B.M.K.H.; All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Mohammad Jahid Hasan or A. B. M. Kamrul-Hasan.

Ethics declarations

Ethics approval and consent to participate

The study received ethical permission from the institutional review board of Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh (Ref. no.: BSMMU/2021/4786–211; Date: 20 November 2021). Informed written consent was taken from the study subjects. The all authors declare no human subjects were harmed and the procedures followed were in accordance with the ethical standards and regulations established by the Helsinki Declaration of the World Medical Association.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Selim, S., Alam, M.S., Talukder, S.K. et al. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study. BMC Endocr Disord 23, 268 (2023). https://doi.org/10.1186/s12902-023-01522-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-023-01522-z

Keywords

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us